At Chimerix, we’re dedicated to preventing
and treating life-threatening viral infections.
Incorporated in 2000, Chimerix is a biopharmaceutical company committed to the discovery, development, and commercialization of novel oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Our proprietary technology has led us to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid conjugate that has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Brincidofovir has shown in vitro activity against all five families of DNA viruses that affect humans, including CMV, adenovirus, BK virus and herpes simplex viruses.
We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measureable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.
We make commitments and live up to them. By empowering individuals to take ownership and harnessing the agility of our organization, we are able to deliver on our promises—exceeding expectations of quality, value and timeliness.
We are entrepreneurs who leverage both scientific ingenuity and business expertise to develop creative solutions that transform our industry.
We hold ourselves to the highest standards of ethical behavior, demonstrating honesty, fairness, and professionalism in every action that we take.
We embrace unique talents, honor diverse life and work styles, value the contributions of others, and treat everyone with dignity.
We promote an environment of trust and conduct ourselves with openness and candor in order to foster collaboration throughout our organization.